Trial reportBJOG : an international journal of obstetrics and gynaecology2006
A randomised trial of carbetocin versus syntometrine in the management of the third stage of labour.
Trial report in BJOG : an international journal of obstetrics and gynaecology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 5 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis.The Cochrane database of systematic reviews · 2025Pooled it
- Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis.The Cochrane database of systematic reviews · 2018Pooled it
- The effect of carbetocin compared to misoprostol in management of the third stage of labor and prevention of postpartum hemorrhage: a systematic review.Systematic reviews · 2018Pooled it
- Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis.The Cochrane database of systematic reviews · 2018Pooled it
- Carbetocin for preventing postpartum haemorrhage.The Cochrane database of systematic reviews · 2012Pooled it
- Carbetocin in the Prevention of Postpartum Hemorrhage after Vaginal Birth: A Systematic Review and Meta-Analysis.Maternal-fetal medicine (Wolters Kluwer Health, Inc.) · 2026Article
- An explorative analysis of pharmacovigilance data of oxytocin and its analogue carbetocin, with a focus on haemodynamic adverse effects.International journal of clinical pharmacy · 2023Article
- Carbetocin versus Oxytocin for the Prevention of Postpartum Hemorrhage in Cesarean Deliveries: A Retrospective Study of Two Consecutive Periods.AJP reports · 2020Article
- Carbetocin vs. Syntometrine in Prevention of Postpartum Hemorrhage: a Double Blind Randomized Control Trial.Iranian Red Crescent medical journal · 2013Article
- Counselling patients with uterine fibroids: a review of the management and complications.Obstetrics and gynecology international · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSyntometrine is an effective uterotonic agent used in preventing primary postpartum haemorrhage but has adverse effects including nausea, vomiting, hypertension and coronary artery spasm. Carbetocin is a newly developed long-acting oxytocin analogue that might be used as an uterotonic agent. We compare the efficacy and safety of intramuscular (IM) carbetocin with IM syntometrine in preventing primary postpartum haemorrhage.
designProspective, double-blinded, randomised controlled trial.
settingDelivery suite of a university-based obstetrics unit. POPULATION: Women with singleton pregnancy achieving vaginal delivery after and throughout 34 weeks.
methodsThree hundred and twenty-nine eligible women were randomised to receive either a single dose of 100 microgram IM carbetocin or 1 ml IM syntometrine (a mixture of 5 iu oxytocin and 0.5 mg ergometrine) at the end of second stage of labour.
main outcome measuresDifference in haemoglobin drop measured 2 days after delivery between the two groups.
resultsThere was no difference in the drop of haemoglobin concentration within the first 48 hours between the two groups. The incidence of additional oxytocic injections, postpartum haemorrhage (blood loss > or = 500 ml) and retained placenta were also similar. The use of carbetocin was associated with significant lower incidence of nausea (relative risk [RR] 0.18, 95% confidence interval [CI] 0.04-0.78), vomiting (RR 0.1, 95% CI 0.01-0.74), hypertension 30 minutes (0 versus 8 cases, P < 0.01) and 60 minutes (0 versus 6 cases, P < 0.05) after delivery but a higher incidence of maternal tachycardia (RR 1.68, 95% CI 1.03-3.57).
conclusionsIM carbetocin is as effective as IM syntometrine in preventing primary postpartum haemorrhage after vaginal delivery. It is less likely to induce hypertension and has a low incidence of adverse effect. It should be considered as a good alternative to conventional uterotonic agents used in managing the third stage of labour.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.